TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04836650

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Postural stability assessment with a force platform.
Description: The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postural stability assessment with a force platform.
Description: The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscular assessment with a electromyograph
Description: The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscular assessment with a electromyograph
Description: The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
Study: NCT04704011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-1-1 United Way Healthy Missouri Hotline
Description: This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National Comprehensive Cancer Network (NCCN) Distress Thermometer
Description: Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic needs survey
Description: 11-item survey with questions regarding safety, housing, food, and financial needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-1-1 survey
Description: This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Reminder Call
Description: -Automated phone call two weeks before their colposcopy appointment
Study: NCT04707651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula diet
Description: Formula diet for 12 weeks
Study: NCT06081582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week
Study: NCT06181565

Intervention type: OTHER
Intervention: Datas of Medistim machine
Description: Datas will be collected by Medistim machine before and after pericardial closure: Flow through the grafts, Resistance on grafts, Pulsatility of the grafts, Systolic and diastolic curves before and after pericardial closure
Study: NCT06294522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reconstruction of alveolar cleft
Description: after elevation of mucoperiosteal flap related to cleft side. suturing of nasal floor and palatal tissue. harvesting of autogenous graft and reconstruction of nasal floor and labial plate of cleft then suturing of flap labially without tension
Study: NCT06189560

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB
Description: the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
Study: NCT05106829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program with treadmill training without using of ankle weights.
Description: The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program with treadmill training with using of ankle weights.
Description: he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
Study: NCT06485440

Intervention type: DRUG
Intervention: Dysport 300 UNT Injection
Description: 300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
Study: NCT04827745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLINCYTO (Blinatumomab)
Description: Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLINCYTO (Blinatumomab)
Description: Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
Study: NCT04834856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
Study: NCT05537688

Intervention type: BEHAVIORAL
Intervention: Identification of Graphic Markers
Description: The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team.

Intervention type: BEHAVIORAL
Intervention: Identification of Graphic Markers
Description: The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team.

Intervention type: BEHAVIORAL
Intervention: Identification of Graphic Markers
Description: The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team.
Study: NCT01648335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)
Study: NCT05900882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60 mg/day, orally on d1,8,15,22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3mg/m2 intravenously on d1,8,15,22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
Study: NCT06316102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender Affirming Abriendo Puertas (Opening Doors) (GAP)
Description: Multilevel intervention with 4 components
Study: NCT05430399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT04862546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupoint
Description: Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tap water iontophoresis
Description: Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes.
Study: NCT05228587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green will be injected in all donor
Study: NCT06248970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube feeding
Description: The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
Study: NCT04925973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 MG [Xeljanz]
Description: Tofacitinib 10mg PO BID
Study: NCT03487926

Intervention type: RADIATION
Intervention: [18F]FEPPA
Description: up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI

Intervention type: RADIATION
Intervention: [18F]FEPPA
Description: up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI

Intervention type: RADIATION
Intervention: [18F]FEPPA
Description: up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI
Study: NCT06525961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTEAR100 Neurostimulator
Description: To apply an iTEAR100 Neurostimulator for the stimulation to the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
Study: NCT05749289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-octreotide
Description: Al18F-octreotide I was injected into the patients before the PET/CT scans
Study: NCT04805775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane Inhalation
Description: Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalation
Description: Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
Study: NCT06446960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg/ml
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride 1.25 MG/ML
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: 2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
Study: NCT04824924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination of HHT, venetoclax, AZA, G-CSF
Description: HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
Study: NCT05324059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg/ Tramadol 50 mg
Description: Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
Study: NCT05959694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablet
Description: TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
Study: NCT04326504

Intervention type: OTHER
Intervention: No intervention
Description: This will be an observational study, no intervention will be performed

Intervention type: OTHER
Intervention: No intervention
Description: This will be an observational study, no intervention will be performed

Intervention type: OTHER
Intervention: No intervention
Description: This will be an observational study, no intervention will be performed

Intervention type: OTHER
Intervention: No intervention
Description: This will be an observational study, no intervention will be performed
Study: NCT00437723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta [NeoRecormon]
Description: At a dose to achieve and maintain an Hb level of 120-135g/dL.
Study: NCT05324059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral